IGF-1 Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous injection Frequency: Twice daily (with meals) Dose Range: 0.04-0.12 mg/kg twice daily (Increlex prescribing information)
Storage
Lyophilized: N/A (supplied as solution) Reconstituted: 2-8 °C (36-46 °F). Do not freeze. Discard 30 days after first use.
Safety & Contraindications
Safety: Hypoglycemia is the most common and serious adverse effect (FDA black box warning on Increlex) — occurs in up to 50% of patients Must be administered with a meal to reduce hypoglycemia risk Injection site reactions common
Contraindications: Active or suspected malignancy; Allergy to mecasermin or any excipient; Closed epiphyses (for growth indication)
Related Research News
Insulin-Like Growth Factors: IGF-1 and IGF-2 Explained
Insulin-like growth factors IGF-1 and IGF-2 play key roles in growth and development. IGF-1, stimulated by growth hormone, rises 2-3 fold during puberty and acts as both endocrine and local growth factors. IGF-2 supports fetal growth and binds distinct receptors, influencing proliferation and survival.
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.